Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice

Yoshiro Tomishima,Yoichi Ishitsuka,Mitsuru Irikura,Naoya Matsunaga,Tetsumi Irie,Hirokazu Furusho,Shigehiro Ohdo,Minako Nagatome

doi:10.1186/1471-230x-13-21

Yoshiro Tomishima, Yoichi Ishitsuka + Show 6 more

Open Access

https://doi.org/10.1186/1471-230x-13-21

Copy DOI

Journal: BMC gastroenterology	Publication Date: Jan 30, 2013
Citations: 75	License type: cc-by

Affiliation: Kumamoto University

Abstract

BackgroundOverdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice.MethodsHepatotoxicity was induced to ICR male mice by an intraperitoneal injection with APAP (330 mg/kg). The effects of ozagrel (200 mg/kg) treatment 30 min after the APAP injection were evaluated with mortality, serum alanine aminotransferase (ALT) levels and hepatic changes, including histopathology, DNA fragmentation, mRNA expression and total glutathione contents. The impact of ozagrel (0.001-1 mg/mL) on cytochrome P450 2E1 (CYP2E1) activity in mouse hepatic microsome was examined. RLC-16 cells, a rat hepatocytes cell line, were exposed to 0.25 mM N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite of APAP. In this model, the cytoprotective effects of ozagrel (1–100 muM) were evaluated by the WST-1 cell viability assay.ResultsOzagel treatment significantly attenuated higher mortality, elevated serum alanine aminotransferase levels, excessive hepatic centrilobular necrosis, hemorrhaging and DNA fragmentation, as well as increase in plasma 2,3-dinor thromboxane B2 levels induced by APAP injection. Ozagrel also inhibited the hepatic expression of cell death-related mRNAs induced by APAP, such as jun oncogene, FBJ osteosarcoma oncogene (fos) and C/EBP homologous protein (chop), but did not suppress B-cell lymphoma 2-like protein11 (bim) expression and hepatic total glutathione depletion. These results show ozagrel can inhibit not all hepatic changes but can reduce the hepatic necrosis. Ozagrel had little impact on CYP2E1 activity involving the NAPQI production. In addition, ozagrel significantly attenuated cell injury induced by NAPQI in RLC-16.ConclusionsWe demonstrate that the TXA2 synthase inhibitor, ozagrel, dramatically alleviates liver injury induced by APAP in mice, and suggest that it is a promising therapeutic candidate for the treatment of APAP-induced liver injury.

Highlights

Elevation of serum ALT level and survival rate induced by APAP injection in mice We examined changes in ALT level in serum 4 h after treatment with APAP (330 mg/kg), as a measure of hepatic damage
We demonstrated that the APAP-induced increases in serum ALT and plasma 2,3-dinor TXB2 levels, as well as the rise in mortality rate, were drastically attenuated by ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, administered 30 min after the APAP injection
We observed a significant increase in plasma 2,3-dinor TXB2 levels following APAP injection, which is in agreement with previous reports

Summary

Introduction

Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice. Acetaminophen (paracetamol, N-acetyl-p-aminophenol [APAP]) is a widely used analgesic/antipyretic drug with few side effects at therapeutic doses [1]. NAPQI likely mediates injury via hepatic glutathione depletion, oxidative and nitrosative stress, and inflammation. The development and progression of liver injury induced by APAP appears to involve multiple mediators, including reactive oxygen species [13], peroxynitrite [14,15], cytokines [16,17,18,19] and eicosanoids [20,21]

Methods

Results

Conclusion